Despite advances in uncovering the mechanisms that underlie neuroinflammation and
neurodegenerative disease, therapies that prevent neuronal loss remain elusive. Targeting …

Alzheimer's disease (AD) is characterized by extracellular aggregates of amyloid β peptides,
intraneuronal tau aggregates, and neuronal death. This pathology triggers activation of …

The loss of dopamine (DA) neurons within the substantia nigra pars compacta (SNpc) is a
defining pathological hallmark of Parkinson's disease (PD). Nevertheless, the molecular …

A key aspect of nearly all single-cell sequencing experiments is dissociation of intact tissues
into single-cell suspensions. While many protocols have been optimized for optimal cell …

Resolving glial contributions to Alzheimer's disease (AD) is necessary because changes in
neuronal function, such as reduced synaptic density, altered electrophysiological properties …

Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals …

The gene-regulatory landscape of the brain is highly dynamic in health and disease,
coordinating a menagerie of biological processes across distinct cell types. Here, we …

Cerebrovascular dysregulation is a hallmark of Alzheimer's disease (AD), but the changes
that occur in specific cell types have not been fully characterized. Here, we profile single …

Alzheimer's disease (AD) predominantly occurs as a late onset (LOAD) form involving
neurodegeneration and cognitive decline with progressive memory loss. Risk factors that …

Dementia in Alzheimer's disease progresses alongside neurodegeneration,,–, but the
specific events that cause neuronal dysfunction and death remain poorly understood. During …